CN115385843A - 一种新型的酰化胰岛素类似物 - Google Patents

一种新型的酰化胰岛素类似物 Download PDF

Info

Publication number
CN115385843A
CN115385843A CN202210567043.2A CN202210567043A CN115385843A CN 115385843 A CN115385843 A CN 115385843A CN 202210567043 A CN202210567043 A CN 202210567043A CN 115385843 A CN115385843 A CN 115385843A
Authority
CN
China
Prior art keywords
cooh
oeg
human insulin
insulin analog
desb30 human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210567043.2A
Other languages
English (en)
Chinese (zh)
Inventor
郑宝液
雷丹
王海刚
林树珊
詹志柱
王茜
刘秋燕
胡杨凌
杨子兰
蒋燕
李文佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Lake Pharma Co Ltd
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of CN115385843A publication Critical patent/CN115385843A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202210567043.2A 2021-05-24 2022-05-23 一种新型的酰化胰岛素类似物 Pending CN115385843A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021105700306 2021-05-24
CN202110570030 2021-05-24

Publications (1)

Publication Number Publication Date
CN115385843A true CN115385843A (zh) 2022-11-25

Family

ID=84115321

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210567043.2A Pending CN115385843A (zh) 2021-05-24 2022-05-23 一种新型的酰化胰岛素类似物

Country Status (8)

Country Link
US (1) US20240374692A1 (https=)
EP (1) EP4347632A4 (https=)
JP (1) JP2024521757A (https=)
KR (1) KR20240013778A (https=)
CN (1) CN115385843A (https=)
AU (1) AU2022283328A1 (https=)
CA (1) CA3217734A1 (https=)
WO (1) WO2022247773A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117756914A (zh) * 2023-12-15 2024-03-26 瀚晖制药有限公司 依柯胰岛素的制备方法
WO2024239961A1 (zh) * 2023-05-24 2024-11-28 联邦生物科技(珠海横琴)有限公司 一种胰岛素衍生物及其应用
WO2025098457A1 (zh) * 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
WO2025162138A1 (zh) * 2024-02-04 2025-08-07 乐普健糖药业(重庆)有限公司 一种超长效胰岛素类似物及其制备方法和用途
WO2025228255A1 (zh) * 2024-04-28 2025-11-06 正大天晴药业集团股份有限公司 酰化人胰岛素类似物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025098502A1 (zh) * 2023-11-08 2025-05-15 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125765A2 (en) * 2005-05-26 2006-11-30 Novo Nordisk A/S Acylated insulin with high purity
US20090069215A1 (en) * 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
CN101437849A (zh) * 2006-05-09 2009-05-20 诺沃-诺迪斯克有限公司 胰岛素衍生物
CN102037008A (zh) * 2008-03-18 2011-04-27 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
US20150111820A1 (en) * 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
CN105636979A (zh) * 2013-10-07 2016-06-01 诺和诺德股份有限公司 胰岛素类似物的新衍生物
CN108026156A (zh) * 2015-08-25 2018-05-11 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
US20190169257A1 (en) * 2016-08-02 2019-06-06 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150633B2 (en) * 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
ES2561208T3 (es) * 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
KR20140104994A (ko) * 2011-12-15 2014-08-29 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 인간 인슐린 유사체 및 이의 아실화 유도체
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
ES2908373T3 (es) * 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos
JP2021512124A (ja) * 2018-02-01 2021-05-13 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． ヒトインスリンアナログのアシル化誘導体を含有する医薬組成物及びその調製方法
CN118754967A (zh) * 2019-12-30 2024-10-11 甘李药业股份有限公司 胰岛素衍生物
JP2020117542A (ja) * 2020-05-07 2020-08-06 ノヴォ ノルディスク アー／エス 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125765A2 (en) * 2005-05-26 2006-11-30 Novo Nordisk A/S Acylated insulin with high purity
US20090069215A1 (en) * 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
CN101437849A (zh) * 2006-05-09 2009-05-20 诺沃-诺迪斯克有限公司 胰岛素衍生物
CN102037008A (zh) * 2008-03-18 2011-04-27 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
US20150111820A1 (en) * 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
CN105636979A (zh) * 2013-10-07 2016-06-01 诺和诺德股份有限公司 胰岛素类似物的新衍生物
CN108026156A (zh) * 2015-08-25 2018-05-11 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
US20190169257A1 (en) * 2016-08-02 2019-06-06 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024239961A1 (zh) * 2023-05-24 2024-11-28 联邦生物科技(珠海横琴)有限公司 一种胰岛素衍生物及其应用
WO2025098457A1 (zh) * 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
CN117756914A (zh) * 2023-12-15 2024-03-26 瀚晖制药有限公司 依柯胰岛素的制备方法
WO2025162138A1 (zh) * 2024-02-04 2025-08-07 乐普健糖药业(重庆)有限公司 一种超长效胰岛素类似物及其制备方法和用途
WO2025228255A1 (zh) * 2024-04-28 2025-11-06 正大天晴药业集团股份有限公司 酰化人胰岛素类似物

Also Published As

Publication number Publication date
US20240374692A1 (en) 2024-11-14
WO2022247773A1 (en) 2022-12-01
EP4347632A4 (en) 2025-03-26
EP4347632A1 (en) 2024-04-10
JP2024521757A (ja) 2024-06-04
KR20240013778A (ko) 2024-01-30
CA3217734A1 (en) 2022-12-01
AU2022283328A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
CN115385843A (zh) 一种新型的酰化胰岛素类似物
CN112409460B (zh) 一类glp-1/胰高血糖素受体双重激动剂及其应用
RU2128663C1 (ru) Производные полипептида, обладающие инсулинотропной активностью, фармацевтическая композиция, способы усиления действия инсулина, способы лечения диабета
US9260503B2 (en) Multi-substituted insulins
CN108463468B (zh) 一种人胰岛素或其类似物的酰化衍生物
CA2825611A1 (en) Novel compounds and their effects on feeding behaviour
CN110386975B (zh) 酰化的glp-1衍生物
SG182578A1 (en) Novel compounds and their effects on feeding behaviour
EP4079757A1 (en) Acylated oxyntomodulin peptide analog
CN119278209A (zh) 人胰淀素类似物、其衍生物及用途
CN116063455B (zh) 一种glp-1受体和gcg受体共激动多肽衍生物及其应用
CN118684758A (zh) 肠促胰岛素类似物及其应用
CN119343368A (zh) 一种人胰淀素多肽衍生物及其用途
CN116970062B (zh) 一种超长效glp-1多肽衍生物及其制备方法和用途
CN110759991B (zh) 吉非罗齐-非洲爪蟾胰高血糖素样肽-1衍生物及其应用
JP2008546816A (ja) エキセンディン４ポリペプチドフラグメントおよびその使用
CN110862448A (zh) 两性离子多肽修饰的glp-1衍生物及其制备方法和应用
CN116589536B (zh) 一类长效glp-1/gip受体双重激动剂及其应用
KR20250177378A (ko) Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물
HK40106360A (zh) 酰化胃泌酸调节素肽类似物
HK40101394A (zh) 酰化胃泌酸调节素肽类似物
TW202613157A (zh) 一種多肽激動劑，其製備方法及醫藥用途
CN120209113A (zh) 一类长效glp-1/gip/y2受体三重激动剂及其制备方法和应用
HK1255297B (en) Acylated derivative of human insulin or analogue thereof
HK1255297A1 (en) Acylated derivative of human insulin or analogue thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Applicant after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd.

Address before: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province

Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd.

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination